Edoxaban Versus Dalteparin in Cancer-Associated VTE – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Nick van Es et al, adding:
”The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai VTE Cancer trial
Novel win ratio analysis comparing edoxaban versus dalteparin in cancer-associated VTE reveals no significant difference between treatments when evaluating hierarchically prioritized outcomes including mortality, recurrent events, and bleeding complications.”
Title: The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai Venous Thromboembolism Cancer trial
Authors: Nick van Es, Luuk Scheres., Kristen Sanfilippo, Harry Buller, Marc Carrier, Marcello Di Nisio, Michael A. Grosso, Renato D. Lopes, William McIntyre, Björn Redfors, Annelise Segers, Peter Verhamme, Jeff Weitz, Patrick Bossuyt, Deborah Siegal
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 6, 2026, 06:25Katherine Bridge: My First Time at The EHA ReCon
-
Apr 6, 2026, 06:11Priya Prasad: Family Donations Are Not as Safe as We Usually Think
-
Apr 6, 2026, 05:48Isaac Okello: Turning Point from Reliance on Foreign Exports to Self – Reliance Through Local Production of Medical Supplies
-
Apr 6, 2026, 05:34Lena Volland: Scientific Exchange in Bleeding Disorders at the WFH 2026 World Congress
-
Apr 6, 2026, 04:46Ursula Porage Dona: Bringing the Bleeding Disorders Community Together at WFH 2026 with NNHF
-
Apr 6, 2026, 04:17Arun V J: How War Reshaped Blood Transfusion
-
Apr 6, 2026, 03:57Isabella Cieri: How TEG Is Transforming Vascular Surgery Care
-
Apr 5, 2026, 19:00Kausik Ray: Comparing Lipid Management in France vs. Rest of Europe for High Cardiovascular Risk Patients
-
Apr 5, 2026, 18:22Omar Adwan: Systematic Approach to Blood Smear Examination